Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yes but there are lots of people dreaming in here. Anything that happens in the world for them is a hint to some good news, lol.
Right, besides it, results are not even out yet, and interim data, announced some time ago, has yet to be released.
Two key points:
"The median overall survival for patients receiving standard of care therapy is approximately 15 months and the average five-year survival rate is less than three percent."
and
"Under a May 2017 agreement between Inovio and Regeneron, the combination trial will be solely conducted and funded by Inovio"
it IMO seems once more like if these combo trials won't bring any upfront money for partnerships at the immuno-oncology companies. Not a good thing. This might explain why in my opinion all combo trials seem not to have started yet, waiting for results (and possibly partnership thereafter with upfront money) for PIII L trial.
He was probably bored. Besides that, trial results don't really make that much of a change IMO if first released in a PR or in 8k, besides the fact that they are material event thus IMO an 8k would follow a PR anyway.
The one working on things, lol...
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=135677678
Oh that's right, I forgot you talk to yourself. Keep it up, lol.
Great, but who cares about Cognate's job postings?
Lol, it traded less than 200K $ so far, why bothering?
Mices are great, but not that many lab trials are sizeable for human trials. However, it still seems optimistic.
I don't know what you mean by profound. Trials are already designed with a specific target.
Very confusing post. Truth is simply that there are big companies with big contacts, big money and big power that don't care of smaller companies and when they care is because they want to expand their IPS or their pipeline portfolio. The old mantra "the stock price goes down because of unknown forces" is IMO simply nonsense. But I do understand some ppl prefer to say that instead of finding more obvious reasons. IMO usually it is used by those who don't want to see the obvious.
Why NW most likely didn't pull out has been widely discussed. Someone even speculated that an answer given by an email could hint something.
The close, pay attention to the close.
It's on their website. I believe this info is obviously of Phase I/II and open arms, but still, if they are so confident to write that on their website, they must be very optimistic.
https://www.uclahealth.org/braintumor/biologics
"Researchers at UCLA developed the first personalized vaccine for brain tumors (dendritic cell-based vaccine, or DCVax®). DCVax® has extended survival of many of our glioblastoma patients for more than a year, and some are thriving more than 10 years after their initial diagnosis."
Get informed. There are almost no more shares to be issued right now. Plus IMO news is very imminent.
By the way, the slide itself exactly says "progression/recurrence then other". To be more precise I believe that this "subgroup" of non-treated patients is inclusive of those who didn't want to have Dcvax after PFS and decided for other treatments, those who were unfortunately too sick to start Dcvax and probably passed by shortly thereafter, and possibly even a couple of patients who were lost to follow-up (even though there might be zero of these patients in this subgroup). IMO there's no way to know how many are in the subgroup above and how many are in the subgroup of those who have placebo treatment still ongoing. IMO, the fact that about 90% of patients as of 06/17 were exposed to Dcvax doesn't help much because in my opinion it could be that those not exposed, 10% or 33 patients, could be those who had "progression/recurrence then other" and the "placebo treatment still ongoing" subgroup right now could even be zero.
Nah, you're missing it, let me tell ya.
IMO news is coming...
IMO it's coming...
Something unprecedented could always happen. The futility rec is given at interim when, for what is scientifically and statistically know, would be the most likely outcome of the trial. However, it could always be prooved wrong, though statistically uncommon.
I do not believe, however, that the co. received a halt on screening for futility. It must be something else. IMO worst case scenario is that PFS was not perhaps showing stat differences but it was already quite demonstrable that OS was going well beyond expectations. Immunotherapy takes time to express its strength in the immune system. There was an interesting video on the internet which explained this in further and convincing detail, if I'll find it I'll link that to you.
There is much to go into deep onto those licenses. In a couple of years (or less), I believe some entity would want to have the whole thing together, and IMO it might be Nwbo, Cognate, or both. Now, if that trial prooves correct, I might agree with someone's speculation that one day the two companies could even merge.
September the 22nd..."While anticipating the disclosure of interim blinded data from the Company’s Phase 3 trial"...
Who cares about Phase 5?
You hate management? I am talking about the science, unless you did the usual copy and paste reply. Wake up!
Besides the fact that I have full respect for LL, which is a great professional and a great person, do you know how many principal investigators of a trial thought that their drug was going to be approved but at the very end did not? Start counting all the failed PIII trials and you get the idea, then add all of the PIII trials which didn't indeed fail but still didn't get approval.
Sorry, but the fact that the principal investigator might have some form of optimism (is it?), is not predictive of a trial success, nor of FDA approval.
Not even a couple of millions, IMO there's no naked shorting at all in here. There's simply no need.
That was an interesting lecture. I just went through a couple of posts right now, which I haven't noticed before, and IMO he has by far been very right in predicting the stock price trend.
This is good news. Nothing really new to the message board, but a good news anyhow.
IMO, it's coming...mark my words!
Point is the investigators that IMO should be aware of some form or at least of blinded data of their subgroup of treated patients, I believe would never combo dcvax with ci if they didn't believe dcvax somehow worked and had some form of efficacy. It all now lies on how much of that efficacy is shown in the current p3 trial.
You bet...
Ok thank you.
I was stuck with those who said the same thing while the stock was trading at 0.50, 0.35 and 0.20...
Companies usually go the other way around. Take a look at CLBS and PCT as a quick example.